About
Mark Gaffney is a biotechnology executive focused on ophthalmology and inflammatory/fibrotic disease companies. He is CEO and board member of Calluna Pharma and previously served as CEO of Oxular, after earlier leadership roles as chief business officer and chief operating officer at Vedere Bio. Earlier in his career he held corporate development and legal roles at Cyclerion Therapeutics and Ironwood Pharmaceuticals, and began as an intelligence officer in the U.S. Air Force.
Areas of interest
biotechophthalmologyretinal diseasegene therapydrug deliveryinflammatory diseasefibrotic disease